Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans - Wikidata - awgldk - TriplyDB

Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans

Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans

http://www.wikidata.org/entity/Q35776453

about

Diagnosis and differential diagnosis of hepatic graft versus host disease (GVHD)Physical function and quality of life in patients with chronic GvHD: a summary of preclinical and clinical studies and a call for exercise intervention trials in patients B cells in chronic graft-versus-host disease T follicular regulatory cells in the regulation of B cell responses The Role of Animal Models in the Study of Hematopoietic Stem Cell Transplantation and GvHD: A Historical Overview The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease Models of Lung Transplant Research: a consensus statement from the National Heart, Lung, and Blood Institute workshop.Combined meta-analysis of systemic effects of allogeneic stem cell transplantation and systemic sclerosis.Transplantation of Donor-Origin Mouse Embryonic Stem Cell-Derived Thymic Epithelial Progenitors Prevents the Development of Chronic Graft-versus-Host Disease in Mice.Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition.Administration of anti-CD20 mAb is highly effective in preventing but ineffective in treating chronic graft-versus-host disease while preserving strong graft-versus-leukemia effects The biology of graft-versus-host disease: experimental systems instructing clinical practice.Current issues in chronic graft-versus-host disease.Advances in graft-versus-host disease biology and therapy.Proteasome: target for acute and chronic GVHD?Treatment of chronic graft-versus-host disease with bortezomib CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease.Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.Aberrant B-cell homeostasis in chronic GVHD Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans.Local origin of mesenchymal cells in a murine orthotopic lung transplantation model of bronchiolitis obliterans.Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease.Advances in understanding the pathogenesis of graft-versus-host disease.Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways Prevention of graft-vs.-host disease H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease.Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation.Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism.Antibodies are back for thymic attack in cGVHD.Antibodies from donor B cells perpetuate cutaneous chronic graft-versus-host disease in mice.Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantation Circulating T follicular helper cells with increased function during chronic graft-versus-host disease Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.Post-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation.Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality.Donor B cells in transplants augment clonal expansion and survival of pathogenic CD4+ T cells that mediate autoimmune-like chronic graft-versus-host disease.Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.

P2860

Q26749007-892D95F3-DC00-461D-9765-6099A18BF8F2 Q26787230-FDEE7D44-514F-4058-940B-F94B59F89327 Q26861706-AE45C222-8140-4FA0-AA11-0342842C6488 Q27006903-9F506985-13B3-4F1C-8A49-1C5034F3B528 Q28066083-0CD8D2BB-569D-4D6C-857C-C168B0DFF3A5 Q28076264-2914B6C6-5A19-4791-9294-D4652CED1E20 Q30352802-E64388D0-50D1-4C0D-8562-DA40AF09C17A Q33614372-6697623C-9453-4443-829A-322F02194D63 Q33722135-190534BE-7B8A-421C-9B88-7169AA2F7996 Q33781179-B5DF7569-F2BF-44B1-8F48-6077D0F4C917 Q33798102-5D53D97F-F235-4516-8E9D-E3B28440280E Q33905411-50D13224-42D4-4337-9508-7CA9D1180F34 Q33917175-8AB4920A-8C7F-480B-A4B3-85CBF62CFAA6 Q33917187-D35CF51B-EF86-4481-96EC-D38E335A8D1A Q34031916-54F6F969-CC22-4EF4-9D61-58A9E1EA7C43 Q34136973-8759785F-B78A-436E-8A21-E04E06716CF2 Q34137032-853A1F6D-4ACA-47CD-94A2-3F503FAD7B1D Q34311645-2984FDB5-8A0B-47AC-AA2E-B519828F31FB Q35140097-CA519BF4-D6E3-48B7-891B-38E201F1BDC5 Q35171251-22389EF2-B398-40EA-894E-55B117635A84 Q35607308-56BDA18D-3DE3-415C-8971-827A0F9257F3 Q35669011-119DD9F7-2F2F-4FDE-AE50-89932246E81F Q35766798-7E040919-CC55-47DC-BA6C-5891AF8DD0BF Q35784522-B934BC91-804A-4EBB-9613-E95EC6D875EB Q35971439-AD504BC8-DA6A-4523-A083-02D485886217 Q36057911-E52A66EC-51B1-4707-A167-7EC88C01704B Q36250962-0D2557CA-2465-40BA-B7D0-6FD21A8F5612 Q36431047-495175B9-7082-453F-B742-E7F67D20A93B Q36637621-8D577578-2CF2-4B38-917F-204A3E17C727 Q36712018-F3995899-5326-4E7C-B3CC-10D89846AA58 Q36851405-CED36018-43F1-43DD-864C-296498AE12B7 Q36876960-75CC6B78-CCF7-4C68-B850-F2434E30F087 Q36876981-06FB451C-746C-4581-B9AF-840BC1449E30 Q36891433-A3B18AA5-E851-4946-8121-AA95D3891B55 Q36920466-243C0E16-FC40-41A7-8B8F-C6E6D9461A20 Q36940174-874A393B-A241-44CC-BE9C-C554F599E2BE Q37029856-21B88721-8E69-4F0E-AA39-4608F52A2316 Q37042232-690C5011-0815-4439-9DA9-F691B9034AAB Q37104281-467D60FD-CE49-485E-8674-80E5CAE1158F Q37113099-790D9EDB-42E2-426A-8B99-AE6E789F2C88

P2860

Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans

http://www.wikidata.org/entity/Q35776453

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Donor B-cell alloantibody depo ...... D and bronchiolitis obliterans

@ast

Donor B-cell alloantibody depo ...... D and bronchiolitis obliterans

@en

type

label

Donor B-cell alloantibody depo ...... D and bronchiolitis obliterans

@ast

Donor B-cell alloantibody depo ...... D and bronchiolitis obliterans

@en

prefLabel

Donor B-cell alloantibody depo ...... D and bronchiolitis obliterans

@ast

Donor B-cell alloantibody depo ...... D and bronchiolitis obliterans

@en

P1433

Q35776453-9C7BEA86-D6B2-4807-AEE8-5DE009C40975

P1476

Q35776453-6BBAA254-46A0-4B51-BE2E-04BB56AEDC66

P2093

Q35776453-0E01CE25-F448-4EAC-84E9-6A58E5471A2E

Q35776453-35A56650-32D1-44F6-B8D4-64348AD67457

Q35776453-6001AE20-8209-4F5E-B419-011A07CB11A8

Q35776453-61C31065-90C9-4A3B-834C-F8EBD50634AF

Q35776453-6FA3275F-260F-4486-847C-185F39FB6927

Q35776453-7E4F9CE1-218D-4B52-8F1F-6ADFDCED1182

Q35776453-9A5D6747-7640-49D4-A416-91CC00199725

Q35776453-B3F2EE31-D120-4751-B9F7-2F6F66C5C63E

Q35776453-FAF6C234-F979-408D-BFB2-E374BCA65CAF

P2860

Q35776453-0136190D-F388-447C-85FD-9577FFBE1AF4

Q35776453-01ECB193-06A4-4CDD-9B0B-B710ACCAF0EA

Q35776453-1E54E872-7AD3-448D-B080-E65F3BB0F6C5

Q35776453-2DF9E3D3-C60E-4AB8-B59F-91DEF9BB7D04

Q35776453-2E37B74A-CD37-458C-8BD6-38702292F4D9

Q35776453-30FC745F-8D7C-48A7-B26F-C7928A3C41E2

Q35776453-387F8208-804C-4B47-B190-ACA731A088C0

Q35776453-3C4039F9-803F-4106-84E5-D5E4DA4B96FA

Q35776453-3CF72FB0-16F8-4D29-80FC-AB23BE23DA14

Q35776453-43DE9DA7-78A1-4874-BDFE-5D33A32A4BBA

P304

Q35776453-8820594A-0BC6-4BF2-9CA5-CB971C8C73EE

P31

Q35776453-A82328E0-D5DA-4028-A51A-7FBA8198B1E2

P356

Q35776453-A77986BE-70F7-47AC-BDCE-EDF379556920

P407

Q35776453-C2B4B9E5-5280-49A3-A75E-E159BF6F130C

P433

Q35776453-9DBB8CBD-6746-4190-AD56-E30CBDFAB5F5

P478

Q35776453-35A3B0C0-BF8B-4D9A-9AFF-9C761501A9F9

P50

Q35776453-5B7C86CE-5919-4F91-AC1B-620721E8FD57

Q35776453-BC398566-A0B8-4173-B750-AB1352B23AA4

Q35776453-EACED34D-94EA-41AB-8F51-D71711226B0B

Q35776453-F6E01F73-2EBE-42E4-81BB-937BA344E480

P577

Q35776453-6F9C5D03-C0E4-4B57-A749-BDF909DBAFBC

P5875

Q35776453-FCBA8FC8-270D-42D8-A3A9-75C36D4EC03F

P698

Q35776453-D49A7C3B-E9F9-4846-91DC-A56DDF22EC6B

P921

Q35776453-0E14EEAF-3C50-4A8C-A0AB-3888B76F7DD6

P932

Q35776453-20D603F5-CA60-4AD9-A24C-4D4C335B76BF

P356

BLOOD-2011-07-364414

P1433

P1476

Donor B-cell alloantibody depo ...... D and bronchiolitis obliterans

@en

P2093

Andrew Price

http://www.w3.org/2001/XMLSchema#string

Ann Ranger

http://www.w3.org/2001/XMLSchema#string

Joseph H Antin

http://www.w3.org/2001/XMLSchema#string

Leo Luznik

http://www.w3.org/2001/XMLSchema#string

Mark J Shlomchik

http://www.w3.org/2001/XMLSchema#string

Mathangi Srinivasan

http://www.w3.org/2001/XMLSchema#string

Patricia A Taylor

http://www.w3.org/2001/XMLSchema#string

Ryan Flynn

http://www.w3.org/2001/XMLSchema#string

William J Murphy

http://www.w3.org/2001/XMLSchema#string

P2860

Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission

Chronic graft-versus-host disease (GVHD) in children.

Salivary gland involvement in chronic graft-versus-host disease: prevalence, clinical significance, and recommendations for evaluation.

High levels of B-cell activating factor in patients with active chronic graft-versus-host disease.

The germinal center reaction.

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

B cells move to centre stage: novel opportunities for autoimmune disease treatment.

The tumor necrosis factor family member LIGHT is a target for asthmatic airway remodeling

Lymphotoxin/light, lymphoid microenvironments and autoimmune disease.

Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease

P304

1570-1580

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-07-364414

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P50

Jeffrey L. Browning

Angela Panoskaltsis-Mortari

P577

2011-11-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51786025

http://www.w3.org/2001/XMLSchema#string

P698

22072556

http://www.w3.org/2001/XMLSchema#string

P921

P932

3286218

http://www.w3.org/2001/XMLSchema#string